OTCMKTS:SDMHF Sartorius Stedim Biotech (SDMHF) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free SDMHF Stock Alerts $207.75 -12.25 (-5.57%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$207.75▼$207.7550-Day Range$207.75▼$299.8652-Week Range$175.12▼$321.11Volume73 shsAverage Volume347 shsMarket CapitalizationN/AP/E Ratio48.20Dividend Yield0.58%Price TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartShort InterestStock AnalysisAnalyst ForecastsChartShort Interest Get Sartorius Stedim Biotech alerts: Email Address Sartorius Stedim Biotech MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearishDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment-0.01Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.04 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Sartorius Stedim Biotech. Previous Next 0.0 Short Interest Percentage of Shares ShortedShort Interest Ratio / Days to CoverSartorius Stedim Biotech has a short interest ratio ("days to cover") of 68.8, which indicates bearish sentiment.Change versus previous monthShort interest in Sartorius Stedim Biotech has recently increased by 78.24%, indicating that investor sentiment is decreasing significantly. Previous Next 0.8 Dividend Strength Dividend YieldSartorius Stedim Biotech has a dividend yield of 0.84%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthSartorius Stedim Biotech does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Sartorius Stedim Biotech is 27.84%. This payout ratio is at a healthy, sustainable level, below 75%. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SDMHF. Previous Next 1.1 News and Social Media Coverage News SentimentSartorius Stedim Biotech has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Sartorius Stedim Biotech this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sartorius Stedim Biotech insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 9.21% of the stock of Sartorius Stedim Biotech is held by institutions. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Sartorius Stedim Biotech is 48.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 146.11.Price to Earnings Ratio vs. SectorThe P/E ratio of Sartorius Stedim Biotech is 48.20, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 260.31. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About Sartorius Stedim Biotech Stock (OTCMKTS:SDMHF)Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.Read More SDMHF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SDMHF Stock News HeadlinesApril 27, 2024 | americanbankingnews.comSartorius Stedim Biotech S.A. (OTCMKTS:SDMHF) Short Interest UpdateApril 17, 2024 | markets.businessinsider.comSartorius Stedim Biotech is about to announce its earnings — here's what Wall Street expectsMay 2, 2024 | Porter & Company (Ad)#1 election stockI’ve found the number one company to buy… Before either Trump or Biden wins in November. It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power. February 28, 2024 | morningstar.comSartorius Stedim Biotech SA ADR SRTOYFebruary 20, 2024 | finance.yahoo.comSartorius Stedim Biotech S.A. (SDMHF)February 7, 2024 | marketwatch.comSartorius Stedim Biotech Shares Fall After Capital IncreaseFebruary 7, 2024 | marketwatch.comSartorius Stedim Biotech Completes $1.3 Bln Capital IncreaseJanuary 26, 2024 | markets.businessinsider.comSartorius Stedim Biotech publishes preliminary, unaudited results for fiscal 2023 and provides 2024 guidance as well as new midterm outlookMay 2, 2024 | Porter & Company (Ad)#1 election stockI’ve found the number one company to buy… Before either Trump or Biden wins in November. It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power. October 19, 2023 | finance.yahoo.comSARTORIUS (SARTF) Q3 Earnings Lag EstimatesJuly 21, 2023 | markets.businessinsider.comSartorius Stedim Biotech SA: Half-year results 2023 of Sartorius Stedim BiotechJuly 21, 2023 | markets.businessinsider.comSartorius Stedim Biotech H1 Profit, Orders Down; Backs Weak FY23 OutlookApril 20, 2023 | markets.businessinsider.comSartorius Stedim Biotech Q1 Profit Declines, Sales Revenue Down 18.4% Organically; Confirms OutlookJanuary 26, 2023 | markets.businessinsider.comSartorius Stedim Biotech FY22 Profit Rises, Orders Down; Sees Growth In FY23; Raises FY25 Sales ViewJanuary 26, 2023 | technews.tmcnet.comPreliminary results 2022 of Sartorius Stedim BiotechOctober 19, 2022 | finance.yahoo.comNine-month results 2022 of Sartorius Stedim BiotechJuly 21, 2022 | markets.businessinsider.comSartorius Stedim Biotech H1 Profit Climbs; Confirms FY22 Outlook - Quick FactsApril 21, 2022 | investing.comSartorius Stedim Earnings Miss, Revenue Beats In Q1April 21, 2022 | seekingalpha.comSartorius Stedim Biotech S.A. Non-GAAP EPS of €2.21, revenue of €862.5MFebruary 8, 2022 | seekingalpha.comSartorius Stedim acquires Novasep's chromatography division; boosts sales guidanceJanuary 28, 2022 | seekingalpha.comSartorius Stedim Biotech Non-GAAP EPS of €7.46, revenue of €2.89BNovember 17, 2021 | benzinga.comSingle-use Bioreactors Market worth $8.8 billion by 2026 – Major Players are Sartorius Stedim Biotech (France), Thermo Fisher Scientific (US)November 16, 2021 | finance.yahoo.comLooking for a Growth Stock? 3 Reasons Why SARTORIUS (SARTF) is a Solid ChoiceAugust 23, 2021 | finance.yahoo.comMcMaster, Sartorius Stedim Biotech team up to advance biomanufacturing processes with next-gen techSee More Headlines Receive SDMHF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sartorius Stedim Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Medical Instruments & Supplies Sub-IndustryN/A Current SymbolOTCMKTS:SDMHF CUSIPN/A CIKN/A Webwww.sartorius.com Phone(344) 284-5600FaxN/AEmployees10,493Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio51.04 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Rene Faber (Age 49)CEO & DIrector Comp: $578.14kMr. Rainer Lehmann (Age 49)CFO & Member of Executive Board Ms. Petra MullerHead of Investor RelationsMs. Petra Kirchhoff (Age 55)Head of Corporate Communications & IR Olivier GuitardHead of Controlling BPSKey CompetitorsAddLife AB (publ)OTCMKTS:ADDLFAnsellOTCMKTS:ANSLYAnsellOTCMKTS:ANSLFAsahi InteccOTC:AHICFBATM Advanced CommunicationsOTCMKTS:BTAVFView All Competitors SDMHF Stock Analysis - Frequently Asked Questions Should I buy or sell Sartorius Stedim Biotech stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sartorius Stedim Biotech in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" SDMHF shares. View SDMHF analyst ratings or view top-rated stocks. How have SDMHF shares performed in 2024? Sartorius Stedim Biotech's stock was trading at $263.75 on January 1st, 2024. Since then, SDMHF stock has decreased by 21.2% and is now trading at $207.75. View the best growth stocks for 2024 here. Are investors shorting Sartorius Stedim Biotech? Sartorius Stedim Biotech saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 34,400 shares, an increase of 78.2% from the March 31st total of 19,300 shares. Based on an average daily volume of 500 shares, the short-interest ratio is presently 68.8 days. View Sartorius Stedim Biotech's Short Interest. Is Sartorius Stedim Biotech a good dividend stock? Sartorius Stedim Biotech (OTCMKTS:SDMHF) pays an annual dividend of $1.20 per share and currently has a dividend yield of 0.84%. The dividend payout ratio is 27.84%. This payout ratio is at a healthy, sustainable level, below 75%. How do I buy shares of Sartorius Stedim Biotech? Shares of SDMHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:SDMHF) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace😱 This phenomenon is smashing regular market gainsMillPubDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyAI “wealth window” is closing June 25thParadigm Press4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sartorius Stedim Biotech S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
